After the Supreme Court ruling, Obamacare IS here to stay—but it will be challenged and it will change long after Obama leaves office, says Dan Eaton.» Read More
The New York State Supreme Court ruled on Thursday that New York City's ban on big sodas, which was blocked by lower courts, is illegal.
The word "unexpectedly" for negative economic data has become a much-mocked cliché, but this week's first-quarter GDP number deserves an exception. The Fiscal Times reports.
Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.
The U.S. Food and Drug Administration warned that popular acne products can cause rare but serious and life-threatening allergic reactions.
A crisis of GM proportions awaits the US if we don't fix some big problems like tax reform and Social Security, says Loews co-chair Andrew Tisch.
Most insurers in Florida aren't disclosing their Obamacare rates for next year because they say they are trade secrets.
The uninsured rate in the US has fallen due to Obamacare, but the wide ranges of rates in individual states could actually grow wider.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
The British Medical Association voted on Tuesday in favor of a lifelong ban on cigarette sales to people born after 2000.
A longtime contraction in employer health-care spending is set to end in 2015 and resume an upward trend, according to a forecast.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
A government agency is claiming that the VA's own investigation of itself holds contradictions, CNBC has learned.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Expanding Medicaid eligibility will significantly affect uninsured rates in seven major cities, and bring them billions in federal money, according to a study.
Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.
Genetics startup 23andMe said it is one step closer to resuming sales of its full-fledged health product.
Wealthy Americans worry about the impact of high health care costs in old age, and see it as one of the biggest risks to their financial security.
People who had their old health care plans canceled aren't necessarily paying higher premiums under Obamacare, according to a Kaiser Family Foundation survey.
Get the best of CNBC in your inbox